Trileptal, an anticonvulsant or antiepileptic drug (AED), was approved for use as an adjunctive and monotherapy for the treatment of partial seizures in adults with epilepsy and for the adjunctive treatment of partial seizures in children, ages 4-16, with epilepsy. It is the first AED to be approved as a monotherapy in several years.
2.3 million Americans have been diagnosed with epilepsy. This year, 181,000 more Americans (children and adults) will develop epilepsy and seizures.
Recent trials include 6 multi-center randomized double blind controlled trials that were conducted to determine the effectiveness of the drug. 4 of the studies investigated the drug as a monotherapy. Participants in these trials ranged from 8 to 66 years old. Two of the studies tested the drug as an adjunctive therapy.
In studies in which the drug was compared to a placebo, patients given the drug lasted significantly longer without having certain seizures than did those patients not taking the drug.
Furthermore, a higher dosage of the drug yielded a significantly longer period before the patient demonstrated specific seizure symptoms.
In addition, two trials, one in which patients were ages 15-66 and the other in which patients were ages 3-17, examined Trileptal as an adjunctive therapy. Every patient in these trials was on 1-3 concomitant Anti-Epileptic Drugs. In both studies, dosage was increased over a period of two weeks until the patient reached the assigned dose or experienced an intolerance to the dosage.
Results of the pediatric trial indicated that compared to a placebo, patients taking the study medication experienced over 25% greater reduction of frequency of partial seizures.
In the adult study, the reduction of frequency of partial seizures for those taking the study drug at the lowest dose was over 18% greater than those taking the placebo, while at the highest dose was over 42% greater than those taking the placebo.
The most common side effects include, but are not limited to:
Some patients also exhibited hyponatremia (low serum sodium levels). Most patients who developed this side effect, were asymptomatic. In clinical trials, patients whose treatment was discontinued due to hyponatremia, generally experienced normalization of serum sodium within a few days without additional treatment.
Some additional side effects were associated with the central nervous system (CNS). These include:
In clinical trials, patients' discontinuation of therapy due to these CNS side effects was dose related when the drug was used as an adjunctive therapy; higher dosages increased the discontinuation rate. No discontinuation of treatment due to similar side effects was found when the drug was used as a monotherapy.
Trileptal should not be used in patients with a known hypersensitivity to oxcarbazepine or to any of its components.
The pharmacological activity of Trileptal (oxcarbazepine) is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine… The precise mechanism by which oxcarbazepine and MHD exert their antiseizure effect is unknown; however in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in the stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and dimunition of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain. In addition, increased potassium conduction and modulation of high-voltage activated calcium channels may contribute to the anticonvulsive effects of the drug. No significant interactions of oxcarbazepine or MHD with brain neurotransmitter or modulator receptor sites have been demonstrated. (from FDA Label)
This is what the Epilepsy Foundation says to do and not to do if you encounter a person having an epileptic seizure:
What To Do:
What Not To Do:
The Trileptal (oxcarbazepine) Tablets drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.